Whilst GLP-1 receptor agonists are not prescribed solely for hypertension management, certain patient populations may derive particular benefit from their blood pressure-lowering effects alongside their primary metabolic indications
Meanwhile, states get to decide whether to cover the drugs under Medicaid
The documented efficacy in diabetes management and the considerable cardiovascular advantages associated with particular GLP-1 agonists are two key drivers moving this industry ahead
Evidence review: Berberine for weight loss and metabolic health Berberine has demonstrated significant potential in managing metabolic health and obesity through various mechanisms
These drugs work, but they are prescription-only, expensive, and often come with gastrointestinal side effects that make long-term use tricky
Meet the experts: Lauren Streicher, MD, is a clinical professor of obstetrics and gynecology at Northwestern University Feinberg School of Medicine